REG-4basebio Plc: Director Appointment, Board Change

4BasebioAnnouncement

Tue 10:45

8 July 2025

4basebio PLC

("4basebio" or the "Company")

Director Appointment, Board Change

Cambridge, UK, 8 July 2025 – 4basebio PLC (AIM: 4BB), an innovation-led
provider of novel synthetic DNA products and a non-viral, thermostable nucleic
acid delivery platform, announces the appointment of Dr. Manja Hermina
Elisabeth Maria Boerman as Executive Chair of the Company with immediate
effect.

The Director appointment and board change follow the investment by (i) Fort
Aggregator LP, acting by its general partner, Elevage Medical Technologies
("Elevage"), a Patient Square Capital platform, initially announced on 29 July
2024 and subsequently updated on 9 September 2024.

As previously announced, Elevage was granted board appointment rights to
appoint a number of directors, including one of their appointees as Chair of
the Board.  Accordingly, the Company announces the appointment of Dr. Manja
Boerman to the Board of Directors and as Chair of the Board.

Consequently, Mr. Timothy McCarthy, who has served as a long-term Director and
Chair of the Board, will be stepping down following this appointment.  Tim
has served as Chair of the Board of 4basebio PLC since its spin-out from
2Invest AG on 8 December 2020, as well as previously on the Board of 2Invest
AG from August 2016 to December 2020. 

In his capacity as Chair, Tim has been instrumental in the growth and success
of 4basebio, including the most recent fundraise which brought Elevage and M&G
Investment Management Limited onto the Company’s share register. He has
acted as a long-term advisor to the executive team and the Company wishes to
express its gratitude and thanks for his ongoing direction and support.

Dr. Manja Boerman, Executive Chair

Dr. Manja Boerman is an experienced biopharmaceutical executive with over 20
years of leadership experience in protein, cell, and gene therapy. Dr. Boerman
currently serves as Director of Linge Bio Holding BV since 2025 and holds
non-executive directorships at Syngene International and Siegfried DiNamiqs
both since 2024. She was also a director at Centrient Pharmaceuticals from
2021 to 2025. In addition, Dr. Boerman was briefly appointed interim CEO of
Prothya Biosolutions from November to December 2024. Her previous roles
include senior leadership at Catalent Pharma Solutions, Aesica
Pharmaceuticals, Opnostics, Patheon Biologics, DSM, and Kiadis Pharma.

Dr. Boerman holds a PhD in Biochemistry from the University at Buffalo and
began her career with research roles at Buffalo and Nijmegen Universities.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of Dr Manja Hermina Elisabeth
Maria Boerman (aged 59):

 Current Directorships             Previous Directorships held in the past five years         
 Linge Bio Holding BV              Catalent Düsseldorf GmbH                                   
 Linge Biologics BV (Netherlands)  Catalent Maryland, Inc                                     
 Siegfried DiNamiqs AG             Catalent Oxford Limited                                    
 Syngene International Limited     Catalent Pharma Solutions, LLC                             
                                   Centrient Pharmaceuticals Netherlands B.V.                 
                                   Linge Biosciences BV (Netherlands)                         
                                   Prothya Biosolutions Belgium - UK Branch                   
                                   Prothya Biosolutions Belgium BV                            
                                   Société d'Infrastructures, de Services et d'Energies NV    
                                   HCTS SA                                                    
                                   SCTS SA                                                    

Dr. Boerman holds no Ordinary Shares, and no options or warrants over Ordinary
Shares. There is no further information regarding Dr. Boerman that is required
to be disclosed under the AIM Rules.

Dr. Heikki Lanckriet, CEO of the Company, said: “As we move into our next
phase of commercial delivery, Manja’s experience at the intersection of
science, strategy, and manufacturing is an ideal match for 4basebio as we
accelerate our commercial growth and scale our platform.

“Her experience in building and growing biologics manufacturing
organisations will support our ambition to become the partner of choice for
high-quality synthetic DNA.”

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the market abuse
(amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

 4basebio PLC Dr. Heikki Lanckriet, CEO                                                               +44 (0)1223 967 943  
 Nominated Adviser        Cairn Financial Advisers LLP Jo Turner / Sandy Jamieson / Ed Downes         +44 (0)20 7213 0880  
 Joint Broker RBC Capital Markets Kathryn Deegan / Matthew Coakes                                     +44 (0)20 7653 4000  
 Joint Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks                              +44 (0)20 7220 0500  

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2025 PR Newswire Association,LLC. All Rights Reserved